Position of the Transparency Council – Tecartus (brexucabtagene autoleucel)

At its meeting on 17 June 2024, the Transparency Council adopted position No. 58/2024 on the evaluation of the drug Tecartus (brexucabtagene autoleucel) as part of the drug program “Treatment of patients with acute leukemia lymphoblastic leukemia (ICD-10: C91.0)”.

Publication of the position >>